threat to influenza and viral respiratory infections

  • Innovative drug for the treatment and prevention of influenza A, B and viral respiratory infections
  • Unique mechanism to address (It is not an interferon inducer)
  • Convenient drug regimen (one capsule per day one time during 5-7 days)
  • High safety profile

In January 2019, it was decided to include imidazolyl ethanamide pentanioic acid (Ingavirin® active ingredient) in the international drug classification system. In the system, the drug coded as - ATH - J05AX21 "Other antiviral drugs"1.

Indications for drug

The treatment and prevention of influenza A, B and other acute viral respiratory infections (adenovirus infection, parainfluenza virus, respiratory syncytial virus).

1 WHO Collaborating Centre for Drug Statistics Methodology website: https://www.whocc.no/atc_ddd_index/updates_included_in_the_atc_ddd_index/new_atc_codes_2019